Pharmacological and biochemical interactions between opioids and cannabinoids
- PMID: 10390647
- DOI: 10.1016/s0165-6147(99)01339-5
Pharmacological and biochemical interactions between opioids and cannabinoids
Abstract
Opioids and cannabinoids are among the most widely consumed drugs of abuse in humans. A number of studies have shown that both types of drugs share several pharmacological properties, including hypothermia, sedation, hypotension, inhibition of both intestinal motility and locomotor activity and, in particular, antinociception. Moreover, phenomena of cross-tolerance or mutual potentiation of some of these pharmacological effects have been reported. In recent years, these phenomena have supported the possible existence of functional links in the mechanisms of action of both types of drugs. The present review addresses the recent advances in the study of pharmacological interactions between opioids and cannabinoids, focusing on two aspects: antinociception and drug addiction. The potential biochemical mechanisms involved in these pharmacological interactions are also discussed together with possible therapeutic implications of opioid-cannabinoid interactions.
Similar articles
-
Molecular and cellular basis of cannabinoid and opioid interactions.Pharmacol Biochem Behav. 2005 Jun;81(2):360-8. doi: 10.1016/j.pbb.2005.01.021. Pharmacol Biochem Behav. 2005. PMID: 15927245 Review.
-
Cannabinoids and reward: interactions with the opioid system.Crit Rev Neurobiol. 2004;16(1-2):147-58. doi: 10.1615/critrevneurobiol.v16.i12.160. Crit Rev Neurobiol. 2004. PMID: 15581410 Review.
-
Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses.Eur Neuropsychopharmacol. 2003 Dec;13(6):401-10. doi: 10.1016/j.euroneuro.2003.08.001. Eur Neuropsychopharmacol. 2003. PMID: 14636956 Review.
-
Cannabinoid/opioid crosstalk in the central nervous system.Crit Rev Neurobiol. 2004;16(1-2):159-72. doi: 10.1615/critrevneurobiol.v16.i12.170. Crit Rev Neurobiol. 2004. PMID: 15581411 Review.
-
Advances in the field of cannabinoid--opioid cross-talk.Addict Biol. 2008 Jun;13(2):213-24. doi: 10.1111/j.1369-1600.2008.00107.x. Addict Biol. 2008. PMID: 18482431 Review.
Cited by
-
Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966.Front Pharmacol. 2022 Apr 21;13:803331. doi: 10.3389/fphar.2022.803331. eCollection 2022. Front Pharmacol. 2022. PMID: 35529434 Free PMC article.
-
Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Delta(9)-tetrahydrocannabinol.Neurotox Res. 2002 May;4(3):211-8. doi: 10.1080/10298420290023936. Neurotox Res. 2002. PMID: 12829401
-
[Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain].Anaesthesist. 2006 Apr;55(4):391-400. doi: 10.1007/s00101-005-0963-6. Anaesthesist. 2006. PMID: 16389542 Clinical Trial. German.
-
Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats.Proc Natl Acad Sci U S A. 2006 May 16;103(20):7877-82. doi: 10.1073/pnas.0602661103. Epub 2006 May 9. Proc Natl Acad Sci U S A. 2006. PMID: 16684876 Free PMC article.
-
Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats.Psychopharmacology (Berl). 2012 Feb;219(4):1111-8. doi: 10.1007/s00213-011-2442-x. Epub 2011 Aug 20. Psychopharmacology (Berl). 2012. PMID: 21858449
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
